{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:44:32Z","timestamp":1787589872797,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1151915"],"award-info":[{"award-number":["OPP1151915"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tuberculosis (TB) preventive therapy is recommended for all people living with HIV (PLHIV). Despite the elevated risk of TB amongst PLHIV, most of those eligible for preventive therapy would never develop TB. Tests which can identify individuals at greatest risk of disease would allow more efficient targeting of preventive therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used mathematical modelling to estimate the potential impact of using a blood transcriptomic biomarker (RISK11) to target preventive therapy amongst PLHIV. We compared universal treatment to RISK11 targeted treatment and explored the effect of repeat screening of the population with RISK11.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Annual RISK11 screening, with preventive therapy provided to those testing positive, could avert 26% (95% CI 13\u201334) more cases over 10\u2009years compared to one round of universal treatment. For the cost per case averted to be lower than universal treatment, the maximum cost of the RISK11 test was approximately 10% of the cost of preventive therapy. The benefit of RISK11 screening may be greatest amongst PLHIV on ART (compared to ART na\u00efve individuals) due to the increased specificity of the test in this group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Biomarker targeted preventive therapy may be more effective than universal treatment amongst PLHIV in high incidence settings but would require repeat screening.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-021-02127-w","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T01:02:29Z","timestamp":1635469349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study"],"prefix":"10.1186","volume":"19","author":[{"given":"Tom","family":"Sumner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Mendelsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Scriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"2127_CR1","unstructured":"Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Review). Cochrane Libr. 2005;2."},{"key":"2127_CR2","doi-asserted-by":"crossref","unstructured":"Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons (Review). Cochrane Database Syst Rev. 2010;2010(1):CD000171.","DOI":"10.1002\/14651858.CD000171.pub3"},{"key":"2127_CR3","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva","author":"World Health Organisation","year":"2018","unstructured":"World Health Organisation. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva; 2018."},{"key":"2127_CR4","volume-title":"Global Tuberculosis Report Geneva","author":"World Health Organisation","year":"2019","unstructured":"World Health Organisation. Global Tuberculosis Report Geneva 2019 [Available from: https:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"issue":"1","key":"2127_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","volume":"12","author":"MX Rangaka","year":"2012","unstructured":"Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45\u201355. https:\/\/doi.org\/10.1016\/S1473-3099(11)70210-9.","journal-title":"Lancet Infect Dis"},{"issue":"9777","key":"2127_CR6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","volume":"377","author":"T Samandari","year":"2011","unstructured":"Samandari T, Agizew T, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(11)60204-3.","journal-title":"Lancet."},{"key":"2127_CR7","doi-asserted-by":"crossref","unstructured":"Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Chir B, et al. A trial of mass isoniazid preventive therpay for tuberculosis control. NEJM. 2014;370(4):301-10.","DOI":"10.1056\/NEJMoa1214289"},{"issue":"3","key":"2127_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1473-3099(20)30914-2","volume":"21","author":"TJ Scriba","year":"2021","unstructured":"Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis. 2021;21(3):354\u201365. https:\/\/doi.org\/10.1016\/S1473-3099(20)30914-2.","journal-title":"Lancet Infect Dis"},{"key":"2127_CR9","unstructured":"World Health Organisation. Consensus meeting report: development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. Geneva; 2017."},{"issue":"10035","key":"2127_CR10","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/S0140-6736(15)01316-1","volume":"387","author":"DE Zak","year":"2016","unstructured":"Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet. 2016;387(10035):2312\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(15)01316-1.","journal-title":"Lancet."},{"key":"2127_CR11","doi-asserted-by":"crossref","unstructured":"Suliman S, Thompson E, Sutherland J, Weiner Rd J, MOC O, Shankar S, et al. Four-gene Pan-African blood signature predicts progression to tuberculosis. Am J Respir Crit Care Med. 2018;197(9):1198-208.","DOI":"10.1164\/rccm.201711-2340OC"},{"issue":"4","key":"2127_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(19)30282-6","volume":"8","author":"RK Gupta","year":"2020","unstructured":"Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas A, et al. Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respir Med. 2020;8(4):395\u2013406. https:\/\/doi.org\/10.1016\/S2213-2600(19)30282-6.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"2127_CR13","doi-asserted-by":"publisher","first-page":"e0237574","DOI":"10.1371\/journal.pone.0237574","volume":"15","author":"H Mulenga","year":"2020","unstructured":"Mulenga H, Zauchenberger CZ, Bunyasi EW, Mbandi SK, Mendelsohn SC, Kagina B, et al. Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: a systematic review and meta-analysis. PLoS One. 2020;15(8):e0237574. https:\/\/doi.org\/10.1371\/journal.pone.0237574.","journal-title":"PLoS One"},{"issue":"6","key":"2127_CR14","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1016\/S2214-109X(21)00045-0","volume":"9","author":"SC Mendelsohn","year":"2021","unstructured":"Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, et al. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. Lancet Glob Health. 2021;9(6):e841\u201353. https:\/\/doi.org\/10.1016\/S2214-109X(21)00045-0.","journal-title":"Lancet Glob Health"},{"key":"2127_CR15","volume-title":"Validation of correlates of risk of TB disease in high risk populations (CORTIS-HR) study: public, subject-level RISK11 signature scores and metadata","author":"SC Mendelsohn","year":"2021","unstructured":"Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung S, Borate B, et al. Validation of correlates of risk of TB disease in high risk populations (CORTIS-HR) study: public, subject-level RISK11 signature scores and metadata. https:\/\/doiorg\/1025375\/uct14176484v1. 2021."},{"key":"2127_CR16","volume-title":"The ten-year incidence of clinical tuberculosis following \u201cconversion\u201d in 2550 individuals aged 14 to 19\u2009years The Hague","author":"I Sutherland","year":"1968","unstructured":"Sutherland I. The ten-year incidence of clinical tuberculosis following \u201cconversion\u201d in 2550 individuals aged 14 to 19\u2009years The Hague. The Netherlands: KNCV; 1968."},{"issue":"6","key":"2127_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/cid\/cir951","volume":"54","author":"JR Andrews","year":"2012","unstructured":"Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis. 2012;54(6):784\u201391. https:\/\/doi.org\/10.1093\/cid\/cir951.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2127_CR18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/QAI.0b013e31820b07ab","volume":"56","author":"A Cattamanchi","year":"2011","unstructured":"Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56(3):230\u20138. https:\/\/doi.org\/10.1097\/QAI.0b013e31820b07ab.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2127_CR19","doi-asserted-by":"crossref","unstructured":"Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177-84.","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"2127_CR20","doi-asserted-by":"publisher","first-page":"100707","DOI":"10.1016\/j.eclinm.2020.100707","volume":"31","author":"Y Jo","year":"2021","unstructured":"Jo Y, Gomes I, Flack J, Salazar-Austin N, Churchyard G, Chaisson RE, et al. Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries. EClinicalMedicine. 2021;31:100707. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100707.","journal-title":"EClinicalMedicine."},{"issue":"12","key":"2127_CR21","doi-asserted-by":"publisher","first-page":"e0243102","DOI":"10.1371\/journal.pone.0243102","volume":"15","author":"EL Stockbridge","year":"2020","unstructured":"Stockbridge EL, Loethen AD, Annan E, Miller TL. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: evidence from commercial insurance data. PLoS One. 2020;15(12):e0243102. https:\/\/doi.org\/10.1371\/journal.pone.0243102.","journal-title":"PLoS One"},{"issue":"12","key":"2127_CR22","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.5588\/ijtld.18.0370","volume":"22","author":"HY Kim","year":"2018","unstructured":"Kim HY, Hanrahan CF, Martinson N, Golub JE, Dowdy DW. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. Int J Tuberc Lung Dis. 2018;22(12):1435\u201342. https:\/\/doi.org\/10.5588\/ijtld.18.0370.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"2127_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5588\/ijtld.15.0391","volume":"20","author":"S Kapoor","year":"2016","unstructured":"Kapoor S, Gupta A, Shah M. Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis. 2016;20(1):85\u201392. https:\/\/doi.org\/10.5588\/ijtld.15.0391.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"2127_CR24","doi-asserted-by":"publisher","first-page":"e36001","DOI":"10.1371\/journal.pone.0036001","volume":"7","author":"MT Pho","year":"2012","unstructured":"Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, et al. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7(4):e36001. https:\/\/doi.org\/10.1371\/journal.pone.0036001.","journal-title":"PLoS One"},{"issue":"1","key":"2127_CR25","doi-asserted-by":"publisher","first-page":"10093","DOI":"10.1038\/s41598-019-46570-5","volume":"9","author":"NS Wong","year":"2019","unstructured":"Wong NS, Leung CC, Chan KCW, Chan WK, Lin AWC, Lee SS. A longitudinal study on latent TB infection screening and its association with TB incidence in HIV patients. Sci Rep. 2019;9(1):10093. https:\/\/doi.org\/10.1038\/s41598-019-46570-5.","journal-title":"Sci Rep"},{"key":"2127_CR26","doi-asserted-by":"publisher","unstructured":"Churchyard G, Cardenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, et al. Annual tuberculosis preventive therapy for persons with HIV infection. Ann Intern Med. 2021. Online ahead of print. https:\/\/doi.org\/10.7326\/M20-7577.","DOI":"10.7326\/M20-7577"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02127-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-021-02127-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-021-02127-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T01:02:53Z","timestamp":1635469373000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-021-02127-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2127"],"URL":"https:\/\/doi.org\/10.1186\/s12916-021-02127-w","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study uses results from the CORTIS-HR study. The CORTIS-HR study was sponsored by the University of Cape Town and the study protocol was approved by the Institutional Human Ethics Committees of each participating site. All participants provided written informed consent in their language of choice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}